About Us
Transradial Technologies, Inc. is a medical device company focused on developing a novel, minimally invasive transradial vascular closure device, SĀPH™.
SĀPH is designed to offer a “fast, safe, and easy-to-use” closure solution for radial artery punctures created during a full range of interventional procedures including cardiac catheterization, percutaneous coronary revascularization, and peripheral angiography/revascularization.
Transradial Technologies, Inc. has worldwide and exclusive rights to the technology via an agreement with Transradial Holdings, Inc.
Mission
At Transradial Technologies, our mission is to transform vascular access and closure by delivering innovative, patient-focused solutions that improve outcomes, enhance comfort, and streamline clinical workflows. We are committed to advancing interventional cardiology through devices and technologies that combine clinical rigor, simplicity, and innovation.
Vision
Our vision is to establish the new standard of care in transradial closure by ensuring safe, fast, and reliable hemostasis while preserving arterial patency. Designed to eliminate radial artery occlusion and reducing workflow burden, SĀPH aims to improve patient outcomes, staff efficiency, and the overall cath lab experience worldwide.
Meet the Team
-
Randy Hubbell
CEO
Over 30 years of medical device, biotechnology and pharmaceutical industry experience at both large multinationals, such as Boston Scientific Corporation and Johnson & Johnson, and four start-ups that led to three exits, including Cardiva Medical, a vascular closure company that was sold to Haemonetics for $510M. Was CEO for Carmell Corp (NASDAQ: CTCX) from 2016 to 2023, a journey that started with a spin out of Carnegie Mellon University worth $6M to a public merger at $150M.
-
Ron Caputo, MD, FACC, FSCAI
Medical Director, Co-Founder & Co-Inventor
Dr. Caputo is a practicing interventional cardiologist with over 80 authored/co-authored peer-reviewed publications and a history of successful medical device entrepreneurship, including co-founding Angiolink, Corp which was acquired by Medtronic (NYSE: MDT).
-
Steve Green
President, Co-Founder & Co-Inventor
Steve has over 40 years of medical device design and development that includes over 20 US and Int’l patents and multiple regulatory product approvals.
-
David P. Koch
Chief Commercial Officer